Cellectar Biosciences

CLRB · NASDAQ

$1.23+$0.11 (+9.82%)TodayMarket closed · Oct 20, 7:48 PM ET

Prev close $1.12

CLRB analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $11.73 (+853.7% upside)

Low: $10.10
Now: $1.23
High: $15.75

Upgrades and downgrades

The latest rating actions, newest first

CLRB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ladenburg Thalmann	May 15, 2026	Initiates	Buy	$10.00	40%
Maxim Group	Mar 10, 2026	Upgrade	Hold → Buy	$10.00	27%

The case for and against

Updated Sep 25, 2024

Bull case

Cellectar Biosciences Inc. is experiencing a positive trajectory due to substantial increases in projected peak revenues for its phospholipid drug conjugate (PDC) therapeutic, iopofosine 131I, which has seen an increase from approximately $200 million to $340 million by 2030, driven by broader label expansion. The clinical data demonstrating strong efficacy and safety in highly refractory Waldenström macroglobulinemia (WM) patients, along with the drug's benefits in multiple disease settings, enhances the company's attractiveness as a potential acquisition target. Furthermore, there is an expectation for improved response rates over time, particularly as the company prepares for a New Drug Application (NDA) filing in the second half of 2024.

Bear case

Cellectar Biosciences faces a challenging outlook primarily due to the risks associated with clinical trial outcomes, particularly the pivotal study of its lead PDC therapeutic iopofosine, which could significantly impact the company's prospects if results are unfavorable. Additionally, the potential inability to secure adequate funding to sustain operations poses a serious threat to the company's viability. Coupled with heightened competition in the treatment landscape, these factors may lead to diminished adoption rates and adversely affect the anticipated commercial value of its products.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.